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MALAT1a b s t r a c t
MicroRNAs mainly inhibit coding genes and long non-coding RNA expression. Here, we report that
hsa-miR-125b and oncogene SIRT7/oncogenic long non-coding RNA MALAT1 were inversely
expressed in bladder cancer. Hsa-miR-125b mimic down-regulated, whereas hsa-miR-125b inhibi-
tor up-regulated the expression of SIRT7 and MALAT1. Binding sites were conﬁrmed between hsa-
miR-125b and SIRT7/MALAT1. Up-regulation of hsa-miR-125b or down-regulation of SIRT7 inhibited
proliferation, motility and increased apoptosis. The effects of up-regulation of hsa-miR-125b were
similar to that of silencing MALAT1 in bladder cancer as we had previously described. These data
suggest that hsa-miR-125b suppresses bladder cancer development via inhibiting SIRT7 and
MALAT1.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Bladder cancer is a common malignancy in the world. The most
common subtype of this cancer is urothelial carcinoma. The carci-
nogenesis of urothelial carcinoma of the bladder is not clearly
understood [1].
MicroRNAs (miRNAs) are small non-coding RNAs of about 22
nucleotides in length that negatively regulate coding gene [2]
and long non-coding RNA (lncRNA) expression [3]. They are aber-
rantly expressed and act as oncogenes or tumor suppressors in
cancer [4].
Hsa-miR-125b is down-regulated in cancer [5,6]. We previously
found that hsa-miR-125b was down-regulated in bladder cancer
[7]. In silico analysis indicated SIRT7 and lncRNA metastasis-asso-
ciated lung adenocarcinoma transcript 1 (MALAT1) were predict-
able targets of hsa-miR-125b. SIRT7 is a mammalian sirtuin
family member, which is up-regulated in breast cancer [8]. Butits expression pattern in bladder cancer is not known. MALAT1 is
overexpressed in several cancers [9]. We previously identiﬁed that
MALAT1 was up-regulated and played oncogenic roles in bladder
cancer [10].
In this study, hsa-miR-125b was down-regulated, whereas
SIRT7 and MALAT1 were up-regulated in bladder cancer. SIRT7
and MALAT1 were identiﬁed as targets of hsa-miR-125b. Hsa-
miR-125b inhibited bladder cancer cell growth, induced apoptosis
and decreased cell motility via down-regulating SIRT7 and
MALAT1.
2. Materials and methods
2.1. Patient samples
Twenty-seven patients with bladder urothelial carcinomas and
paired adjacent histologically normal tissues and 12 patients with
bladder urothelial carcinomas were included in the study. We
obtained the informed consent from all the patients and the
approval of the study from the Institutional Review Board of the
Second People’s Hospital of Shenzhen, Shenzhen, China.
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Bladder cancer T24 and 5737 cells, urothelial SV-HUC-1 cells
and human embryo kidney 293T cells (HEK 293T, 293T) were
purchased from the Institute of Cell Research, Chinese Academy
of Sciences, Shanghai, China. The SV-HUC-1 cells were cultured in
F-12K (Corning, Manassas, VA, USA) plus 10% fetal bovine serum.
The other cells were cultured in Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM) (Invitrogen, Carlsbad, CA, USA) plus 10% fetal
bovine serum.
SIRT7 siRNA (target sequence: 50-CTCACCGTATTTCTACTACTA-
30) and Allstars Negative Control siRNA were purchased from
Qiagen, Hilden, Germany. Hsa-miR-125b mimic/negative control
mimic and hsa-miR-125b inhibitor/negative control inhibitor were
purchased from Ribo, Guangzhou, China. The SIRT7 ORF containing
pReceiver vector (SIRT7 ORF vector) and the control pReceiverFig. 1. Expression of hsa-miR-125b, SIRT7 and MALAT1 in bladder cancer. (A) The relativ
cancer. Data are shown as mean ± S.E.M. (A) Hsa-miR-125b was down-regulated in bladde
cancer compared with matched urothelium. (C) MALAT1 was up-regulated in bladder
inversely expressed in bladder cancer. In the circle, two dots are overlapping. (E) Hsa
expression levels were evaluated using real-time qPCR in bladder cancer T24 and 5637
three independent times. Data are shown as mean ± S.D. (F) Hsa-miR-125b was down-re
regulated in T24 and 5637 cells compared with SV-HUC-1 cells. (H) SIRT7 was up-regul
Table 1
Hsa-miR-125b, MALAT1 and SIRT7 expression levels in urothelial carcinoma of the bladde
Hsa-miR-125b
2DCt:(hsa-miR-125b-U6) P value
Grade* Low (n = 20) 43.67 ± 8.41 0.012
High (n = 19) 20.01 ± 8.44
Stage# T1N0M0 (n = 10) 48.41 ± 8.47 0.002
T2-3N0M0 (n = 29) 24.13 ± 2.96
Data are shown as mean ± S.E.M.
* World Health Organization 2004 classiﬁcation.
# American Joint Committee on Cancer TNM classiﬁcation.vector (control vector) were purchased from GeneCopoiea Inc,
Rockville, MD, USA.
The cells were incubated with either SIRT7 siRNA/negative con-
trol siRNA, hsa-miR-125b mimic/negative control mimic or hsa-
miR-125b inhibitor/negative control inhibitor using Nanofectin™
Transfection reagent (Excell Bio, Shanghai, China) according to
the protocol. The ﬁnal concentrations of SIRT7 siRNA/negative con-
trol siRNA, hsa-miR-125b mimic/negative control mimic, hsa-miR-
125b inhibitor/negative control inhibitor and SIRT7 ORF vector/
control vector were 20, 100, 200 nM and 1 lg/ml respectively.
2.3. Total RNA extraction and reverse transcription
Total RNA was extracted from the tissues or cells using TRIzol
reagent (Invitrogen, Carlsbad, CA, USA) according to the manufac-
turer’s protocol. Ten micrograms of total RNA was converted toe expression levels were evaluated using real-time qPCR in 27 patients with bladder
r cancer compared with matched urothelium. (B) SIRT7 was up-regulated in bladder
cancer compared with matched urothelium. (D) Hsa-miR-125b and SIRT7 were
-miR-125b and MALAT1 were inversely expressed in bladder cancer. The relative
cells compared with urothelial SV-HUC-1 cells. Each experiment was performed for
gulated in T24 and 5637 cells compared with SV-HUC-1 cells. (G) MALAT1 was up-
ated in T24 and 5637 cells compared with SV-HUC-1 cells.
r.
MALAT1 SIRT7
2DCt(MALAT1-GAPDH) P value 2DCt(SIRT7-GAPDH) P value
3.22 ± 0.97 <0.001 0.42 ± 0.05 <0.001
12.50 ± 1.93 0.86 ± 0.08
3.90 ± 1.11 0.020 0.37 ± 0.09 0.016
8.66 ± 1.58 0.70 ± 0.06
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Copoiea Inc, Rockville, MD, USA) according to the manufacturer’s
protocol.
2.4. Real-time quantitative polymerase chain reaction (qPCR)
qPCR primers against mature miRNA hsa-miR-125b and homo
sapiens snRNA U6 were purchased from GeneCopoiea Inc,
Rockville, MD, USA. SIRT7 primers were forward: 50-CGTCCGG
AACGCCAAATAC-30, reverse: 50-GACGCTGCCGTGCTGATT-30; MA-
LAT1 primers were forward: 50-AAAGCAAGGTCTCCCCACAAG-30,
reverse: 50-GGTCTGTGCTAGATCAAAAGGCA-30 [11]; GAPDH
primers were forward: 50-CGCTCTCTGCTCCTCCTGTTC-30, reverse:
50-ATCCGTTGACTCCGACCTTCAC-30. The PCR procedures were as
described elsewhere [7,10]. Hsa-miR-125b was normalized to
snRNA U6. GAPDH was used as an internal control for SIRT7 and
MALAT1. Expression fold changes were calculated using 2DDCt
methods [12].
2.5. Western blot analysis
Antibodies speciﬁc to SIRT7 and GAPDH were purchased from
Santa Cruz, Dallas, Texas, USA. Western blots were performed as
described elsewhere [13].Fig. 2. Expression changes of SIRT7 or MALAT1 after transfection of SIRT7 speciﬁc siRN
expression levels were evaluated using real-time qPCR. Data are indicated as mean ± S.D
was performed in triplicate for three independent times. (A) SIRT7 speciﬁc siRNA signiﬁ
images of Western blot results indicated SIRT7 speciﬁc siRNA signiﬁcantly down-regula
down-regulated the expression of SIRT7 at mRNA levels. (D) Representative images of W
the expression of SIRT7 at protein levels. (E) Hsa-miR-125b inhibitor signiﬁcantly up-regu
blot results indicated that hsa-miR-125b inhibitor signiﬁcantly up-regulated the expressi
MALAT1 expression levels. (H) Hsa-miR-125b inhibitor signiﬁcantly up-regulated MALA2.6. miRNA target prediction
The binding site prediction for hsa-miR-125b within SIRT7
30UTR was performed using miRanda (http://www.microrna.org),
microCosm Targets (http://www.ebi.ac.uk/enright-srv/microcosm
and TargetScan (http://www.Targetscan.org). Binding sites be-
tween hsa-miR-125b and MALAT1 were predicted with miRanda.
2.7. Dual luciferase reporter assay
The fragment 50-caccaggccagtCTCAGGGc-30 (position 316,
NM_016538) from the 30untranslated region (30UTR) of SIRT7 con-
taining the predicted hsa-miR-125b binding site was chemically
synthesized and cloned into the Xhol and Notl sites of the psi-
CHECK-2 vector (Promega, Madison, WI, USA). The resulted vector
was called the reporter vector SIRT7 30UTR-wild-type (WT). The
corresponding mutant construct was created by mutating the
hsa-miR-125b seed region binding site (seed sequence binding
fragment 50-CTCAGGG-30 changed to 50-GAACTAT-30), which was
called the reporter vector SIRT7 30UTR-mutated-type (MUT).
The fragments 50-ttuggcacgaacacctTCAGGGa-30 (position 3386,
NR_002819) and 50-tttatttccagaaagTCAGGGg-30 (position6183,
NR_002819) from MALAT1 containing the predicted hsa-miR-
125b binding site were chemically synthesized and cloned intoA or hsa-miR-125b mimic or inhibitor in T24 and 5637 cells. The relative mRNA
. SIRT7 protein levels were determined using Western blot assay. Each experiment
cantly down-regulated the expression of SIRT7 at mRNA levels. (B) Representative
ted the expression of SIRT7 at protein levels. (C) Hsa-miR-125b mimic signiﬁcantly
estern blot results indicated that hsa-miR-125b mimic signiﬁcantly down-regulated
lated the expression of SIRT7 at mRNA levels. (F) Representative images of Western
on of SIRT7 at protein levels. (G) Hsa-miR-125b mimic signiﬁcantly down-regulated
T1 expression levels.
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resulted vectors were called the reporter vector MALAT1-1-wild-
type (WT) and the reporter vector MALAT1-2-wild-type (WT),
respectively. The corresponding mutants were created by mutating
the hsa-miR-125b seed region binding site (seed sequence binding
fragment 50-TCAGGG-30 changed to 50-AGCAAA-30), which were
called the reporter vector MALAT1-1-mutated-type (MUT) and
the reporter vector MALAT1-2-mutated-type (MUT) respectively.
Hsa-miR-125b mimic or negative control mimic was cotrans-
fected with the reporter vectors containing either the targeting se-
quences or the corresponding mutants using Nanofectin™
Transfection Reagent (Excell Bio, Shanghai, China) according to
the protocol. The luciferase activities were then determined using
a Multimode Detector (Beckman Coulter, CA, USA).
2.8. Cell proliferation assay
Cell proliferation was measured using MTT assay. Cells were
seeded in a 96-well plate and cultured in normal medium. At 0,
24, 48 and 72 h after transfection, the cells were incubated in
0.1 mg/ml MTT at 37 C for 4 h and lysed in dimethyl sulfoxide
(DMSO) at room temperature for 10 min. The absorbance in each
well was measured by a microplate reader (Bio-Rad, Hercules,
CA, USA).
2.9. Cell apoptosis determined by caspase 3 enzyme-linked
immunosorbent assay (ELISA)
Forty-eight hours after transfection, apoptosis caused by SIRT7
siRNA, hsa-miR-125b mimic or hsa-miR-125b inhibitor or SIRT7
ORF vector or control vector was evaluated by analyzing the activ-
ity of caspase 3 using the caspase 3 ELISA assay kit (R&D, Minneap-
olis, MN, USA) according to the manufacturer’s protocol. A
microplate reader (Bio-Rad, Hercules, CA, USA) was used to deter-
mine optical density (OD) values. Data were shown as the ratios
between the OD values of SIRT7 siRNA, hsa-miR-125b mimic or
hsa-miR-125b inhibitor and negative control or SIRT7 ORF vector
and control vector transfected cells.Fig. 3. Hsa-miR-125b mimic reduced the luciferase activities. (A) The predicted hsa-m
underscored. (B) The relative luciferase activities were inhibited in the cells transfected w
vector SIRT7 30UTR-MUT. (C) The ﬁrst predicted hsa-miR-125b binding site located in M
activities were inhibited in the cells transfected with the reporter vector MALAT1-1-WT,
predicted hsa-miR-125b binding site located in MALAT1. Seed sequence and the mutan
transfected with the reporter vector MALAT1-2-WT, not in the cells transfected with the r
performed in triplicate for three independent times.2.10. Wound healing assay
Bladder cancer cells were transfected with SIRT7 siRNA, hsa-
miR-125b mimic, hsa-miR-125b inhibitor or negative control or
SIRT7 ORF vector or control vector. Cells were scratched in the
monolayer and cultured in normal condition. The migrated dis-
tances were measured at 0, 16 h after scratching for T24 cells
and at 0, 24 h after scratching for 5637 cells respectively.
2.11. Immunocytochemical analyses
Bladder cancer cells were transfected with of SIRT7 ORF vector
or control vector. Forty-eight hours after transfection, immunocy-
tochemical analyses were performed as described elsewhere [14].
2.12. Statistical analysis
The expression differences between bladder cancer and
matched urothelium were analyzed using paired samples t-test.
Pearson’s coefﬁcient correlation was used for expression correla-
tion assay. The expression differences between high/low grades,
high/low stages, cell lines, the expression changes after transfec-
tion, luciferase activity, cell apoptosis and wound healing assays
were analyzed using independent samples t-test. MTT assays were
analyzed using ANOVA. The statistical analyses were performed
using SPSS (Version 17.0). P values were two-sided and a value of
<0.05 was considered to be statistically signiﬁcant.
3. Results
3.1. Hsa-miR-125b and SIRT7/MALAT1 were inversely expressed in
bladder cancer
The relative expression levels of hsa-miR-125b, SIRT7 and MA-
LAT1 were evaluated using real-time qPCR in 27 patients with
bladder urothelial carcinomas and paired adjacent histologically
normal tissues and 12 patients with bladder urothelial carcinomas.
Hsa-miR-125b was down-regulated in bladder cancer comparediR-125b binding site located in SIRT7 30UTR. Seed sequence and the mutant are
ith the reporter vector SIRT7 30UTR-WT, not in the cells transfected with the reporter
ALAT1. Seed sequence and the mutant are underscored. (D) The relative luciferase
not in the cells transfected with the reporter vector MALAT1-1-MUT. (E) The second
t are underscored. (F) The relative luciferase activities were inhibited in the cells
eporter vector MALAT1-2-MUT. Data are shown as mean ± S.D. Each experiment was
Fig. 4. Cell proliferation, apoptosis and motility changes caused by transfection of SIRT7 siRNA/hsa-miR-125b mimic/hsa-miR-125b inhibitor. Cell proliferation was measured
by MTT assay. (A) SIRT7 siRNA inhibited T24 and 5637 proliferation. (B) Hsa-miR-125b mimic inhibited T24 and 5637 proliferation. (C) Hsa-miR-125b inhibitor promoted T24
and 5637 proliferation. Cell apoptosis changes were determined by caspase 3 ELISA. (D) SIRT7 siRNA induced T24 and 5637 apoptosis. (E) Hsa-miR-125b mimic induced T24
and 5637 apoptosis. (F) Hsa-miR-125b inhibitor inhibited T24 and 5637 apoptosis. Wound healing assay was used to detect cell motility changes. (G) Representative images
of cell motility changes by transfection of SIRT7 siRNA. (H) SIRT7 siRNA decreased cell motility. (I) Representative images of cell motility changes by transfection of hsa-miR-
125b mimic. (J) Hsa-miR-125b mimic decreased cell motility. (K) Representative images of motility changes by transfection of hsa-miR-125b inhibitor. (L) Hsa-miR-125b
inhibitor increased cell motility. Data are indicated as mean ± S.D. Each experiment in both cell lines was performed in triplicate for three independent times.
Y. Han et al. / FEBS Letters 587 (2013) 3875–3882 3879
3880 Y. Han et al. / FEBS Letters 587 (2013) 3875–3882with matched normal urothelium (n = 27) (Fig. 1A). Both SIRT7 and
MALAT1 were up-regulated in bladder cancer compared with
matched normal urothelium (n = 27) (Fig. 1B and C). Hsa-miR-
125b and SIRT7 were inversely expressed in bladder cancer
(n = 27) (Fig. 1D). Hsa-miR-125b and MALAT1 were also inversely
expressed in bladder cancer (n = 27) (Fig. 1E). We further analyzed
the expression patterns in urothelial carcinomas according to grad-
ing and staging in a total of 39 patients. High-gade and high-stage
carcinomas had higher SIRT7 and MALAT1 expression levels and
lower Hsa-miR-125b expression levels than low-gade and low-
stage carcinomas (Table 1). Hsa-miR-125b expression levels were
lower in bladder cancer T24 and 5737 cells than in urothelial SV-
HUC-1 cells (Fig. 1F). SIRT7 and MALAT1 were more abundant in
T24 and 5737 cells than in SV-HUC-1 cells (Fig. 1G and H).
3.2. Hsa-miR-125b regulated the expression of SIRT7 and MALAT1
Forty-eight hours after transfection, SIRT7 and MALAT1 expres-
sion levels were measured. Both SIRT7 siRNA and hsa-miR-125b
mimic down-regulated SIRT7 at mRNA and protein levels in T24
and 5637 cells (Fig. 2A–D). Hsa-miR-125b inhibitor up-regulated
SIRT7 at mRNA and protein levels in T24 and 5637 cells (Fig. 2E
and F). Hsa-miR-125b mimic markedly down-regulated MALAT1
expression levels in T24 and 5637 cells (Fig. 2G), whereas hsa-
miR-125b inhibitor markedly up-regulated MALAT1 expression
levels in T24 and 5637 cells (Fig. 2H).Fig. 5. Increased SIRT7 expression after transfection of SIRT7 ORF vector. (A) Fluorescen
cells. green, SIRT7; blue, DAPI. (B) The quantiﬁed intensity change in T24 cells is ex
microscopy showed increased expression of SIRT7 in SIRT7 ORF transfected 5637 cells. gr
as mean ± S.E.M. from three independent experiments.3.3. Hsa-miR-125b reduced the luciferase activities
Hsa-miR-125b inhibited the luciferase activities in 293T cells
transfected with the reporter vector SIRT7 30UTR-WT, but not in
293T cells transfected with the reporter vector SIRT7 30UTR-MUT
(Fig. 3A), which indicated the hsa-miR-125b binding site within
SIRT7 30UTR was functional. Hsa-miR-125b inhibited the luciferase
activities in 293T cells transfected with the reporter vector MA-
LAT1-1-WT or MALAT1-2-WT, but not in 293T cells transfected
with the reporter vector MALAT1-1-MUT or the reporter vector
MALAT1-2-MUT (Fig. 3B and C), which indicated both hsa-miR-
125b binding sites within MALAT1 were functional.
3.4. Cell proliferation, apoptosis and motility changes caused by
transfection of SIRT7 siRNA/ hsa-miR-125b mimic/hsa-miR-125b
inhibitor
Cell proliferation inhibition was observed in T24 and 5637 cells
by transfection of SIRT7 siRNA (Fig. 4A) or hsa-miR-125b mimic
(Fig. 4B). Cell proliferation promotion was observed in T24 and
5637 cells by transfection of hsa-miR-125b inhibitor (Fig. 4C).
Increased cell apoptosis was observed in both bladder cancer cells
by transfection of SIRT7 siRNA (Fig. 4D) or hsa-miR-125b mimic
(Fig. 4E). Decreased cell apoptosis was observed in both bladder
cancer cells by transfection of hsa-miR-125b inhibitor (Fig. 4F).
Decreased cell motility was observed in both bladder cancer cellsce microscopy showed increased expression of SIRT7 in SIRT7 ORF transfected T24
pressed as mean ± S.E.M. from three independent experiments. (C) Fluorescence
een, SIRT7; blue, DAPI. (D) The quantiﬁed intensity change in 5637 cells is expressed
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mic (Fig. 4I and J). Increased cell motility was observed in both
bladder cancer cells by transfection of hsa-miR-125b inhibitor
(Fig. 4K and L).
3.5. Transfection of SIRT7 ORF partly reversed the changes caused by
transfection of hsa-miR-125b mimic
The increased expression of SIRT7 protein was observed in
SIRT7 ORF transfected T24 and 5637cells by ﬂuorescence micros-
copy (Fig. 5A–D). SIRT7 ORF vector partly reversed T24 and 5637
proliferation inhibition induced by hsa-miR-125b mimic (Fig. 6A
and B). SIRT7 ORF vector partly reversed T24 and 5637 apoptosis
induced by hsa-miR-125b mimic (Fig. 6C). SIRT7 ORF vector partly
reversed T24 and 5637 motility decrease induced by hsa-miR-125b
mimic (Fig. 6D–G).Fig. 6. Transfection of SIRT7 ORF vector partly reversed the changes caused by transfectio
ORF vector partly reversed T24 proliferation inhibition induced by hsa-miR-125b mimic
by hsa-miR-125b mimic (P < 0.01). Cell apoptosis changes were determined by caspase 3
miR-125b mimic. Wound healing assay was used to detect cell motility changes. (D) Repr
T24 motility decrease induced by hsa-miR-125b mimic. (F) Representative images of 5
decrease induced by hsa-miR-125b mimic. Data are indicated as mean ± S.D. Each exper4. Discussion
In plants, miRNAs mainly direct cleavage of target mRNAs
through perfect base pairing [15]. In animals, miRNAs use two dis-
tinct mechanisms to regulate gene expression. They are able to re-
press translation and/or decrease mRNAs when miRNAs and
mRNAs are partially complementary. miRNAs are able to expedite
poly(A) removal and lead to rapid mRNA decay [16]. In mammalian
cells, miRNAs predominantly decrease target mRNA levels [2]. For
example, miR-1 and miR-133a down-regulate their targets at both
mRNA and protein levels through partial sequence pairing with the
target sites [17].
In this study, the expression levels of hsa-miR-125b were
down-regulated in bladder cancer. Up-regulation of hsa-miR-
125b inhibited bladder cancer cell proliferation, motility and
increased apoptosis. Down-regulation of hsa-miR-125b had then of hsa-miR-125b mimic. Cell proliferation was measured by MTT assay. (A) SIRT7
(P < 0.01). (B) SIRT7 ORF vector partly reversed 5637 proliferation inhibition caused
ELISA. (C) SIRT7 ORF vector partly reversed T24 and 5637 apoptosis induced by hsa-
esentative images of T24 cell motility changes. (E) SIRT7 ORF vector partly reversed
637 cell motility changes. (G) SIRT7 ORF vector partly reversed 5637 cell motility
iment in both cell lines was performed in triplicate for three independent times.
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mor suppressor in bladder cancer.
The mammalian sirtuin family member SIRT7 localizes in the
cytoplasm and the nucleus [18]. It is a highly selective H3K18Ac
deacetylase and plays roles in chromatin regulation and cancer
development [19]. SIRT7 was an in silico predictable target of
hsa-miR-125b. The mature hsa-miR-125b sequence with was par-
tially complementary with SIRT7 30UTR target sequence. The
expression levels of SIRT7 were up-regulated in bladder cancer.
Hsa-miR-125b and SIRT7 were inversely expressed in bladder can-
cer. Hsa-miR-125b mimic down-regulated, whereas hsa-miR-125b
inhibitor up-regulated the expression of SIRT7. Binding site was
conﬁrmed between hsa-miR-125b and SIRT7. Down-regulation of
SIRT7 inhibited bladder cancer cell proliferation, motility and in-
creased apoptosis. These effects were similar to that of up-regu-
lated hsa-miR-125b in bladder cancer cells. Forced expression of
SIRT7 partly reversed the changes caused by transfection of hsa-
miR-125b mimic. These ﬁndings suggested that SIRT7 is an onco-
gene and a true target of hsa-miR-125b in bladder cancer.
Besides coding genes, lncRNAs have been experimentally ver-
iﬁed and computationally predicted targets of miRNAs [3].
LncRNA MALAT1 regulates gene expression and pre-mRNA pro-
cessing [20,21]. We previously identiﬁed that silencing MALAT1
inhibited bladder cancer cell growth, induced apoptosis and de-
creased cell motility [10]. MALAT1 was an in silico predictable
target of hsa-miR-125b. The mature hsa-miR-125b sequence
was partially complementary with MALAT1 target sequences.
The expression levels of MALAT1 were up-regulated in bladder
cancer. Hsa-miR-125b and MALAT1 were inversely expressed
in bladder cancer. Hsa-miR-125b mimic down-regulated,
whereas hsa-miR-125b inhibitor up-regulated the expression
of MALAT1. Binding sites were conﬁrmed between hsa-miR-
125b and MALAT1. The effects of up-regulation of hsa-miR-
125b were similar to that of silencing MALAT1 in bladder can-
cer cells as we had previously described [10]. These ﬁndings
suggested that MALAT1 is a true target of hsa-miR-125b in
bladder cancer.
Taken together, our data suggest that loss of expression of hsa-
miR-125b contributes to the overexpression of SIRT7 and MALAT1
in bladder cancer. By now, the functional relevance between SIRT7
and MALAT1 is not clear. Restoration of hsa-miR-125b suppresses
bladder cancer development via down-regulating SIRT7 and MA-
LAT1, which may have potential therapeutic signiﬁcance.Acknowledgments
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